US trial go-ahead for Thoratec's CABG (coronary artery bypass graft) graft:
This article was originally published in Clinica
Thoratec Laboratories has received permission from the US FDA to begin a clinical trial of its Aria coronary artery bypass graft (CABG) under an investigational device exemption. The AEGIS/US (AlternativE Graft Investigational Study) trial will assess the prosthetic graft, which incorporates the company's proprietary biomaterial Thoralon, in bypass patients who have too few or no suitable vessels of their own. Pleasanton, California-based Thoratec said it was the first company to gain FDA approval to begin US clinical trials for a prosthetic aorta-to-coronary artery bypass graft for such patients. Trials of the graft have been underway in Canada since late last year.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.